Literature DB >> 1547193

Low density lipoproteins inhibit endotoxin activation of monocytes.

C Weinstock1, H Ullrich, R Hohe, A Berg, M W Baumstark, I Frey, H Northoff, W A Flegel.   

Abstract

Human serum and low density lipoproteins (LDLs) were shown to inactivate endotoxin (lipopolysaccharide [LPS]) by testing the effect of LPS interactions with serum or LDL on the activation of human monocytes. Sera and LDL preparations from four patients with familial hypercholesterolemia were used to demonstrate the inhibition of LPS from inducing interleukin-1 release. Before LDL removal by immunoapheresis, the patients' sera were able to inactive approximately fivefold more LPS than after LDL removal. The LPS-inactivating capacity lost during apheresis could essentially be retrieved in the LDL-rich eluate from the immunoadsorption columns. Because patients were treated frequently with immunoapheresis, their LDL levels before LDL removal were not markedly elevated. These patients' sera before LDL removal were shown to inactivate amounts of LPS comparable to those inactivated by the sera from three healthy volunteers. LDL prepared by ultracentrifugation showed similar LPS inactivation as LDL prepared by immunoapheresis. We conclude that the inhibition of LPS-induced monocyte activation by human serum is dependent to a large extent on the LDL fraction. LDLs were demonstrated to inhibit LPS from inducing interleukin-1 release by human monocytes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1547193     DOI: 10.1161/01.atv.12.3.341

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  10 in total

1.  E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide.

Authors:  T Kawata; J R Bristol; D P Rossignol; J R Rose; S Kobayashi; H Yokohama; A Ishibashi; W J Christ; K Katayama; I Yamatsu; Y Kishi
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

2.  Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins.

Authors:  J R Rose; M A Mullarkey; W J Christ; L D Hawkins; M Lynn; Y Kishi; K M Wasan; K Peteherych; D P Rossignol
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  Unilamellar liposomes modulate secretion of tumor necrosis factor by lipopolysaccharide-stimulated macrophages.

Authors:  G F Brisseau; A Kresta; D Schouten; J M Bohnen; P N Shek; E Fok; O D Rotstein
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 4.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

5.  Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I.

Authors:  W A Flegel; M W Baumstark; C Weinstock; A Berg; H Northoff
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

6.  Enhancement of lipopolysaccharide-induced tumor necrosis factor secretion by hyperimmune serum from chronic infected patients.

Authors:  G Kronborg; A Fomsgaard; N Høiby
Journal:  Med Microbiol Immunol       Date:  1993-12       Impact factor: 3.402

7.  Classifying Aging As a Disease: The Role of Microbes.

Authors:  Michael S Lustgarten
Journal:  Front Genet       Date:  2016-12-01       Impact factor: 4.599

8.  Krill Oil-In-Water Emulsion Protects against Lipopolysaccharide-Induced Proinflammatory Activation of Macrophages In Vitro.

Authors:  Gabriel A Bonaterra; David Driscoll; Hans Schwarzbach; Ralf Kinscherf
Journal:  Mar Drugs       Date:  2017-03-15       Impact factor: 5.118

9.  An in vitro study on factors affecting endotoxin neutralization in human plasma using the Limulus amebocyte lysate test.

Authors:  Stephan Harm; Claudia Schildböck; Karin Strobl; Jens Hartmann
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

10.  High-density lipoprotein infusion protects from acute graft-versus-host disease in experimental allogeneic hematopoietic cell transplantation.

Authors:  Cécile Chagué; Thomas Gautier; Ludivine Dal Zuffo; Jean-Paul Pais de Barros; Audrey Wetzel; Georges Tarris; Gaëtan Pallot; Laurent Martin; Séverine Valmary-Degano; Valérie Deckert; Laurent Lagrost; Etienne Daguindau; Philippe Saas
Journal:  Am J Transplant       Date:  2022-02-10       Impact factor: 9.369

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.